HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 364 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $45,467,014 | +12.4% | 1,190,236 | +6.2% | 0.01% | +25.0% |
| Q2 2023 | $40,439,807 | -29.2% | 1,121,148 | -25.1% | 0.00% | -33.3% |
| Q1 2023 | $57,153,473 | -16.4% | 1,496,556 | +24.6% | 0.01% | -25.0% |
| Q4 2022 | $68,331,608 | +53.0% | 1,200,907 | +6.3% | 0.01% | +60.0% |
| Q3 2022 | $44,662,000 | +34.5% | 1,129,544 | +49.7% | 0.01% | +25.0% |
| Q2 2022 | $33,199,000 | +14.3% | 754,525 | +3.6% | 0.00% | +33.3% |
| Q1 2022 | $29,043,000 | +10.5% | 728,252 | +11.4% | 0.00% | 0.0% |
| Q4 2021 | $26,292,000 | -11.8% | 653,857 | -10.8% | 0.00% | 0.0% |
| Q3 2021 | $29,807,000 | -2.9% | 732,698 | +8.4% | 0.00% | 0.0% |
| Q2 2021 | $30,683,000 | -14.9% | 675,648 | -21.8% | 0.00% | -25.0% |
| Q1 2021 | $36,036,000 | +72.7% | 864,369 | +76.9% | 0.00% | +33.3% |
| Q4 2020 | $20,869,000 | +114.3% | 488,609 | +31.9% | 0.00% | +200.0% |
| Q3 2020 | $9,737,000 | +171.2% | 370,509 | +176.7% | 0.00% | 0.0% |
| Q2 2020 | $3,590,000 | +37.1% | 133,910 | -7.9% | 0.00% | – |
| Q1 2020 | $2,618,000 | -30.5% | 145,448 | -31.6% | 0.00% | -100.0% |
| Q4 2019 | $3,769,000 | +14.9% | 212,550 | +0.5% | 0.00% | – |
| Q3 2019 | $3,281,000 | +19.3% | 211,515 | +32.1% | 0.00% | – |
| Q2 2019 | $2,750,000 | +2.4% | 160,098 | -4.1% | 0.00% | – |
| Q1 2019 | $2,686,000 | +306.4% | 166,881 | +269.3% | 0.00% | – |
| Q4 2018 | $661,000 | -20.7% | 45,184 | -1.6% | 0.00% | – |
| Q3 2018 | $834,000 | -70.5% | 45,914 | -72.6% | 0.00% | – |
| Q2 2018 | $2,826,000 | +38.9% | 167,497 | +61.3% | 0.00% | – |
| Q1 2018 | $2,034,000 | +95.4% | 103,843 | +102.1% | 0.00% | – |
| Q4 2017 | $1,041,000 | +0.7% | 51,377 | -13.7% | 0.00% | – |
| Q3 2017 | $1,034,000 | +123.3% | 59,512 | +64.8% | 0.00% | – |
| Q2 2017 | $463,000 | -75.0% | 36,121 | -74.7% | 0.00% | – |
| Q1 2017 | $1,852,000 | +1.4% | 142,930 | -22.7% | 0.00% | – |
| Q4 2016 | $1,827,000 | -7.5% | 184,960 | +13.1% | 0.00% | – |
| Q3 2016 | $1,975,000 | +31.5% | 163,487 | -6.0% | 0.00% | – |
| Q2 2016 | $1,502,000 | -1.6% | 173,993 | +8.0% | 0.00% | – |
| Q1 2016 | $1,526,000 | -77.5% | 161,079 | -58.9% | 0.00% | -100.0% |
| Q4 2015 | $6,786,000 | +49.4% | 391,566 | +15.7% | 0.00% | +100.0% |
| Q3 2015 | $4,543,000 | -44.6% | 338,293 | -6.9% | 0.00% | -66.7% |
| Q2 2015 | $8,205,000 | +72.1% | 363,387 | +8.8% | 0.00% | +50.0% |
| Q1 2015 | $4,768,000 | +118.8% | 333,892 | +47.9% | 0.00% | +100.0% |
| Q4 2014 | $2,179,000 | -1.7% | 225,782 | -7.3% | 0.00% | 0.0% |
| Q3 2014 | $2,216,000 | -4.3% | 243,481 | +4.0% | 0.00% | 0.0% |
| Q2 2014 | $2,315,000 | +7.6% | 234,178 | +38.3% | 0.00% | 0.0% |
| Q1 2014 | $2,151,000 | -44.9% | 169,321 | -35.0% | 0.00% | 0.0% |
| Q4 2013 | $3,904,000 | +4.5% | 260,482 | -23.0% | 0.00% | 0.0% |
| Q3 2013 | $3,736,000 | +28.3% | 338,464 | -7.6% | 0.00% | 0.0% |
| Q2 2013 | $2,912,000 | – | 366,389 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |